Chimeric Therapeutics Limited (CHM)

Overview

Chimeric Therapeutics Limited is positioned at the forefront of oncological advancement as a clinical stage cell therapy company based in Carlton, Australia. Established in 2020, the company is dedicated to pioneering the development and commercialization of innovative cell therapies targeting a broad spectrum of oncological indications. Through its rigorous research and clinical trials, Chimeric Therapeutics Limited is poised to make significant contributions to the field of oncology, aiming to improve patient outcomes and provide new avenues of treatment for various types of cancer.

Products and Services

The therapeutic pipeline of Chimeric Therapeutics Limited comprises several cell therapy candidates at various stages of clinical development, each targeting different cancer types, including solid tumors, hematological malignancies, and specific cancers such as glioblastoma, melanoma, colorectal, prostate, neuroendocrine, pancreatic, and gastric cancers.

• CHM 0201 (core NK platform): Currently in phase I clinical trial, this natural killer (NK) cell therapy platform is designed to target solid tumors and hematological malignancies. Leveraging the innate cancer-fighting properties of NK cells, CHM 0201 aims to offer a potent and versatile treatment option for patients.
• CHM 1101 (CLTX CAR T): This innovative chimeric antigen receptor T (CAR T) cell therapy is in phase I clinical trial for treating MMP2+ recurrent or progressive glioblastoma. By harnessing the specificity of CAR T-cell technology, CHM 1101 seeks to provide targeted therapy against glioblastoma, a notoriously difficult-to-treat brain cancer.
• CHM 0301 for blood cancers: Being developed as a next-generation therapy for various blood cancers, CHM 0301 represents Chimeric Therapeutics Limited's commitment to expanding treatment options for hematological malignancies, though specific details on its mechanism of action and clinical development stage are yet to be disclosed.
• CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors: Both therapies are based on CAR NK cell technology, targeting CDH17 and other antigens expressed on solid tumors. These therapies aim to leverage the natural tumor-killing ability of NK cells, enhanced with CAR technology for greater efficacy against solid tumors.
• CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate cancer: In addition to its application in glioblastoma, CHM 1101 is also being explored for its potential in treating other cancers such as melanoma, colorectal, and prostate cancer, demonstrating the adaptability and broad applicability of CAR T-cell therapy.
• CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric cancer: This CAR T-cell therapy targets CDH17, a marker found on several types of solid tumors. By focusing on CDH17, CHM 2101 aims to offer a novel, targeted treatment option for patients suffering from these challenging-to-treat cancers.